Capricor Therapeutics Inc. (CAPR) will be presenting results from its phase 3 clinical study of lead cell therapy candidate Deramiocel for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy, dubbed HOPE-3, at the Muscular Dystrophy Association Clinical and Scientific Conference on March 11, 2026.
The topline results from the HOPE-3 study, reported last December, were encouraging. The study met the primary endpoint of PUL v2.0 (Performance of Upper Limb) and the key secondary cardiac endpoint of LVEF (Left Ventricular Ejection Fraction), demonstrating statistically significant improvements in both skeletal and cardiac function.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com